Inhibition of key enzymes related to diabetes and hypertension by Eugenol in vitro and in alloxan-induced diabetic rats

Abstract The present study investigated the effect of treating diabetic rats with eugenol (EG). In vitro enzyme activity was measured in the presence of eugenol, and it was found to inhibit pancreatic α-amylase (IC50 = 62.53 µg/mL) and lipase (IC50 = 72.34 µg/mL) as well as angiotensin converting en...

Full description

Saved in:
Bibliographic Details
Published in:Archives of physiology and biochemistry 2013-12, Vol.119 (5), p.225-233
Main Authors: Mnafgui, Kais, Kaanich, Fatima, Derbali, Amal, Hamden, Khaled, Derbali, Fatma, Slama, Sadok, Allouche, Noureddine, Elfeki, Abdelfattah
Format: Article
Language:English
Subjects:
ACE
Animals
Blood Glucose - metabolism
diabetes
Diabetes Mellitus, Experimental - blood
Diabetes Mellitus, Experimental - complications
Diabetes Mellitus, Experimental - drug therapy
Diabetes Mellitus, Experimental - enzymology
eugenol
Eugenol - adverse effects
Eugenol - pharmacology
Eugenol - therapeutic use
Glycated Hemoglobin A - metabolism
Hypertension - complications
Intestine, Small - drug effects
Intestine, Small - enzymology
Kidney - drug effects
Kidney - metabolism
lipase
Lipids - blood
Liver - drug effects
Liver - enzymology
Male
Rats
Rats, Wistar
α-amylase
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The present study investigated the effect of treating diabetic rats with eugenol (EG). In vitro enzyme activity was measured in the presence of eugenol, and it was found to inhibit pancreatic α-amylase (IC50 = 62.53 µg/mL) and lipase (IC50 = 72.34 µg/mL) as well as angiotensin converting enzyme (ACE) activity (IC50 = 130.67 µg/mL). In vivo, EG reduced the activity of amylase in serum, pancreas and intestine also the peak level of glucose by 60% compared to diabetic rats. Furthermore, eugenol similar to acarbose reduced serum glycosylated hemoglobin (HbA1c), lipase and ACE levels. In addition, treatments with EG showed notable decrease in serum total-cholesterol, triglycerides and low density lipoprotein-cholesterol levels with an increase of high density lipoprotein-cholesterol. Overall, EG significantly reverted back to near normal the values of the biochemical biomarkers such as transaminases (AST&ALT), alkaline phosphatase (ALP), creatine phosphokinase (CPK) and gamma-glutamyl transpeptidase (GGT) activities, total-bilirubin, creatinine, urea and uric acid rates.
ISSN:1381-3455
1744-4160
DOI:10.3109/13813455.2013.822521